Back to Authors

Borgsten, F.

A5081503874 | I4405282460

Mayo Clinic

Janssen Research & Development (United States)

Citations 3

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 18-19

10.1097/01.hs9.0000936192.21618.f2

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 14-15

10.1097/01.hs9.0000936164.84357.ed

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 826-827

10.1097/01.hs9.0000846612.13339.9e